These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11507035)

  • 21. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
    Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
    Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
    Baumgaertner P; Rufer N; Devevre E; Derre L; Rimoldi D; Geldhof C; Voelter V; Liénard D; Romero P; Speiser DE
    Cancer Res; 2006 Feb; 66(4):1912-6. PubMed ID: 16488988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
    Hofmann UB; Voigt H; Andersen MH; Straten PT; Becker JC; Eggert AO
    Eur J Immunol; 2009 May; 39(5):1419-24. PubMed ID: 19337999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.
    Sommerfeldt N; Beckhove P; Ge Y; Schütz F; Choi C; Bucur M; Domschke C; Sohn C; Schneeweis A; Rom J; Pollmann D; Leucht D; Vlodavsky I; Schirrmacher V
    Cancer Res; 2006 Aug; 66(15):7716-23. PubMed ID: 16885374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.
    Otto K; Andersen MH; Eggert A; Keikavoussi P; Pedersen LØ; Rath JC; Böck M; Bröcker EB; Straten PT; Kämpgen E; Becker JC
    Vaccine; 2005 Jan; 23(7):884-9. PubMed ID: 15603888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Full-length dominant-negative survivin for cancer immunotherapy.
    Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
    Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
    Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
    Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses.
    Parmiani G; Anichini A; Castelli C
    Melanoma Res; 1997 Aug; 7 Suppl 2():S95-8. PubMed ID: 9578423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
    Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide.
    Gang Y; Zhang X; He Y; Zheng J; Wu K; Ding J; Fan D
    Biochem Cell Biol; 2012 Dec; 90(6):701-8. PubMed ID: 22992138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes.
    Siegel S; Steinmann J; Schmitz N; Stuhlmann R; Dreger P; Zeis M
    Leukemia; 2004 Dec; 18(12):2046-7. PubMed ID: 15470490
    [No Abstract]   [Full Text] [Related]  

  • 36. HLA-B35-restricted immune responses against survivin in cancer patients.
    Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH
    Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.
    Trojan A; Witzens M; Schultze JL; Vonderheide RH; Harig S; Krackhardt AM; Stahel RA; Gribben JG
    Cancer Res; 2001 Jun; 61(12):4761-5. PubMed ID: 11406549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous immunity against Bcl-xL in cancer patients.
    Andersen MH; Reker S; Kvistborg P; Becker JC; thor Straten P
    J Immunol; 2005 Aug; 175(4):2709-14. PubMed ID: 16081848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
    Nagorsen D; Scheibenbogen C; Schaller G; Leigh B; Schmittel A; Letsch A; Thiel E; Keilholz U
    Int J Cancer; 2003 Jun; 105(2):221-5. PubMed ID: 12673683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.
    Andersen MH; Reker S; Becker JC; thor Straten P
    J Invest Dermatol; 2004 Feb; 122(2):392-9. PubMed ID: 15009721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.